Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant modified FOLFIRINOX for resectable pancreatic adenocarcinoma
KCT0004421Phase 2Recruiting
- Sponsor
- Boryung
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by Boryung. Started May 2020; status: recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on KCT0004421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004421.